3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
6
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
165
fludarabine phosphate
110
Peripheral Blood Stem Cell Transplantation
94
Mycophenolic Acid
88
Whole-Body Irradiation
81
Etoposide
81
Tacrolimus
73
Busulfan
68
Melphalan
67
Filgrastim
66
fludarabine
62
Radiotherapy
56
Doxorubicin
54
Cyclosporine
54
Rituximab
50
Brentuximab Vedotin
48
Antilymphocyte Serum
47
Granulocyte Colony-Stimulating Factor
42
Vinblastine
41
Methotrexate
38
Dacarbazine
37
Cytarabine
35
Gemcitabine
34
Nivolumab
30
Bleomycin
29
Carmustine
28
Vincristine
25
Prednisone
25
Sirolimus
24
Bendamustine Hydrochloride
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hodgkin Disease
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts